The regulation and roles of Rel/NF-κB transcription factors during lymphocyte activation

Current Opinion in Immunology

Volumn 10, Issue 3, 1998, Pages 353-359

  Gerondakis, Steve ^a   Grumont, Raelene ^a   Rourke, Ian ^a   Grossmann, Mathis ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

APOPTOSIS; B LYMPHOCYTE ACTIVATION; CELL DIVISION; GENE EXPRESSION; LYMPHOCYTE DIFFERENTIATION; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0031833431     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(98)80175-1     Document Type: Article

References (49)

1. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol. 12:1994;141-179.
2. Verma IM, Stevenson JK, Schwarz EM, van Antwerp DV, Miyamoto S. Rel/NF-κB/lκB family: intimate tails of association and dissociation. Genes Dev. 9:1995;2723-2735.
3. Kontgen F, Grumont RJ, Strasser A, Metcalf D, Li R, Tarlinton D, Gerondakis S. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. 9:1995;1965-1977.
4. Doi TS, Takahashi T, Taguchi O, Takachika A, Obata Y. NF-κB RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses. J Exp Med. 185:1997;953-961.
5. Sha WC, Liou H-C, Toumanen EI, Baltimore D. Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell. 80:1997;321-330.
6. Ishikawa H, Carrasco D, Claudio E, Ryseck R-P, Bravo R. Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-κB2. J Exp Med. 186:1997;999-1014.
7. Weih F, Warr G, Yang H, Bravo R. Multifocal defects in immune responses in RelB-deficient mice. J Immunol. 158:1997;5211-5218.
8. Burkly L, Hession C, Ogata L, Reilly C, Marconi LA, Olsen D, Tizard R, Cate R, Lo D. Expression of relB is required for development of thymic medulla and dendritic cells. Nature. 373:1995;531-536.
9. Horwitz BH, Scott ML, Cherry SR, Bronson RT, Baltimore D. Failure of lymphopoiesis after adoptive transfer of NF-κB-deficient fetal liver cells. Immunity. 6:1997;765-772.
10. -/- double-knockout mice. J Exp Med. 185:1997;1359-1370.
11. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 11:1997;3482-3496.
12. Esslinger CW, Wilson A, Sardat B, Beermann F, Jongeneel CV. Abnormal T lymphocyte development induced by targeted overexpression of IκBα J Immunol. 158:1997;5075-5078.
13. Boothby MR, Mora AL, Scherer DC, Brockman JA, Ballard DW. Perturbation of the T lymphocyte lineage in transgenic mice expressing a constitutive repressor of nuclear factor (NF)-κB. J Exp Med. 185:1997;1897-1907.
14. Scherer DC, Brockman JA, Bendall HH, Zhang GM, Ballard DW, Oltz EM. Corepression of RelA and c-Rel inhibits immunoglobulin κ gene transcription and rearrangement in precursor B lymphocytes. Immunity. 5:1996;563-574.
15. Grumont RJ, Gerondakis S. The subunit composition of NF-κB complexes changes during B-cell development. Cell Growth Differ. 5:1994;1321-1331.
16. Grumont RJ, Rourke IJ, O'Reilly LA, Strasser A, Miyake K, Sha W, Gerondakis S. B lymphocytes diferentially use the Rel and NF-κB1 transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. of special interest J Exp Med. 187:1998;1-12 This study demonstrates for the first time that nuclear factor-κB1 (NF-κB1) and Rel differentially regulate B cell survival in quiescent and mitogen-activated B cells and are required for mitogen-dependent G1 progression.
17. Perkins ND, Felzein LK, Betts JC, Leung K, Beech D, Nabel GL. Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator. Science. 275:1997;523-527.
18. Baichwal VR, Baeuerle PA. Apoptosis: Activate or die? Curr Biol. 7:1997;94-96.
19. Wu M, Lee H, Bellas R, Schauer S, Arsura M, Katz D, FitzGerald MJ, Rothstein TL, Sherr DH, Sonenshein GE. Inhibition of NF-κB/Rel induces apoptosis of murine B cells. EMBO J. 15:1996;4682-4690.
20. Schauer SL, Wang Z, Sonenshein GE, Rothstein TL. Maintenance of nuclear factor-κB/Rel and c-myc expression during CD40 ligand rescue of W231 early B cells from receptor-mediated apoptosis through modulation of IκB proteins. J Immunol. 156:1996;81-86.
21. Snapper CM, Marcu KB, Zelazowski P. The immunoglobulin class switch: beyond "accessibility" Immunity. 6:1997;217-223.
22. Iciek LA, Delphin SA, Stavnezer J. CD40 cross-linking induces IgE germline transcripts in B cells via activation of NF-κB. J Immunol. 158:1997;4769-4779.
23. Michaelson JS, Singh M, Snapper CM, Sha WC, Baltimore D, Birshtein BK. Regulation of 3′ IgH enhancers by a common set of factors, including κB-binding proteins. J Immunol. 156:1996;2828-2839.
24. Snapper CM, Zelazowski P, Rosas FR, Kehry MR, Tian M, Baltimore D, Sha WC. B cells from p50/NF-κB knockout mice have selective defects in proliferation, differentiation, germline CH transcription, and Ig class switching. J Immunol. 156:1996;183-191.
25. H transcription and class switching. J Immunol. 159:1997;3133-3139.
26. Cogne M, Lansford R, Bottaro A, Zhang J, Gorman J, Young F, Cheng H-L, Alt FW. A class switch control region at the 3′ end of the immunoglobulin heavy chain locus. Cell. 77:1994;737-747.
27. Fraser JD, Irving BA, Crabtree GR, Weiss A. Regulation of interleukin-2 gene enhancer activity by the T-cell accessory molecule CD28. Science. 251:1991;313-316.
28. Maggirwar SB, Harhaj E, Sun S-C. Regulation of the interleukin-2 CD28-responsive element by NF-ATp and various NF-κB/Rel transcription factors. Mol Cell Biol. 17:1997;2605-2614.
29. Himes SR, Coles LS, Reeves R, Shannon MF. High mobility group protein I(Y) is required for function and for c-Rel binding to CD28 response elements within the GM-CSF and IL-2 promoters. of special interest Immunity. 5:1996;479-489 This work provides a mechanism for explaining the selective binding of Rel to the CD28 response element.
30. Gerondakis S, Strasser A, Metcalf D, Grigoriadis G, Scheerlinck J-PY, Grumont RJ. Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor. Proc Natl Acad Sci USA. 93:1996;3405-3409.
31. Grigoriadis G, Zhan Y, Grumont RJ, Metcalf D, Handman E, Cheers C, Gerondakis S. The Rel subunit of NF-κB-like transcription factors is a positive and negative regulator of macrophage gene expression: distinct roles for Rel in different macrophage populations. EMBO J. 15:1996;7099-7107.
32. Brown K, Park S, Kanno T, Granzoso G, Seibenlist U. Mutual regulation of the transcriptional activator NF-κB and its inhibitor, IκBα Proc Natl Acad Sci USA. 90:1993;2532-2536.
33. Harhaj EW, Maggirwar SB, Good L, Sun S-C. CD28 mediates a potent costimulatory signal for rapid degradation of IκBβ which is associated with accelerated activation of various NF-κB/Rel heterodimers. of special interest Mol Cell Biol. 16:1996;6736-6743 This demonstrates the differential phosphorylation and degradation of the inhibitor of NF-κBα (IκBα) and IκBβ in response to TCR and CD28 signals and illustrates the basis by which Rel/NF-κB is regulated in a transient or sustained fashion.
34. Thompson JE, Phillips RJ, Erdjument-Bromage H, Tempst P, Ghosh S. IκBβ regulates the persistent response in a biphasic activation of NF-κB. Cell. 80:1995;573-582.
35. Beg AA, Sha WC, Bronson RT, Baltimore D. Constitutive NF-κB activation, enhanced granulopoiesis, and neonatal lethality in IκBα-deficient mice. Genes Dev. 9:1995;2736-2746.
36. Rothe M, Sarma V, Dixit VM, Goeddel DV. TRAF2-mediated activation of NF-κB by TNF receptor 2 and CD40. Science. 269:1995;1424-1427.
37. Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzwieg MC, Choi Y. TRAF2 is essential for JNK but not NF-κB activation and regulates lymphocyte proliferation and survival. of special interest Immunity. 7:1997;703-713 These studies indicate for the first time that tumor necrosis factor receptor associated factor 2 (TRAF2) is not essential for nuclear factor (NF)-κB activation in B cells by CD40.
38. Ishida T, Tojo T, Aoki T, Kobayashi N, Ohishi T, Watanabe T, Yamamoto T, Inoue J-I. TRAF5, a novel TNF receptor associated factor family protein, mediates CD40 signalling. Proc Natl Acad Sci USA. 93:1995;9437-9442.
39. 2+ response amplitude and duration. of special interest Nature. 386:1997;855-858 This paper provides a mechanism to explain how calcium regulated transcription factors are differentially regulated by the amplitude and duration of a calcium flux. Nuclear factor (NF)-κB is specifically activated by a large transient increase in intracellular calcium.
40. Healy JI, Dolmetsch RE, Timmerman LA, Cyster JG, Thaomas ML, Crabtree GR, Lewis RS, Goodnow CC. Different nuclear signals are activated by the B cell receptor during positive versus negative selection. Immunity. 6:1997;419-428.
41. Didonato JA, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. of outstanding interest Nature. 388:1997;548-554 References by Didonato et al. and by Mercurio et al., 1997 [42], Regnier et al., 1997 [43], Woronicz et al., 1997 [45] and Zandi et al., 1997 [46] collectively describe the identification, molecular cloning and characterization of the inhibitor of NF-κB (IκB) kinases IKK-1 and IKK-2.
42. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BI, Li JW, Young DB, Barbosa M, Mann M, Manning A, Rao A. IKK-1 and IKK-2: Cytokine-activated IκB kinases essential for NF-κB activation. of outstanding interest Science. 278:1997;860-866 References by Mercurio et al. and by Didonato et al., 1997 [41], Regnier et al., 1997 [43], Woronicz et al., 1997 [45] and Zandi et al., 1997 [46] collectively describe the identification, molecular cloning and characterization of the inhibitor of NF-κB (IκB) kinases IKK-1 and IKK-2.
43. Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characterization of an IκB kinase. of outstanding interest Cell. 90:1997;373-383 References by Regnier et al. and by Didonato et al., 1997 [41], Mercurio et al., 1997 [42], Woronicz et al., 1997 [45] and Zandi et al., 1997 [46] collectively describe the identification, molecular cloning and characterization of the inhibitor of NF-κB (IκB) kinases IKK-1 and IKK-2.
44. Connelly MA, Marcu KB. CHUK, a new member of the helix-loop-helix and leucine zipper families of interacting proteins, contains a serine-threonine kinase catalytic domain. Cell Mol Biol Res. 41:1995;537-549.
45. Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel. IκB kinase β: NF-κB activation and complex formation with IκB kinase-α and NIK. of outstanding interest Science. 278:1997;866-869 References by Woronicz et al. and by Didonato et al., 1997 [41], Mercurio et al., 1997 [42], Regnier et al., 1997 [43] and Zandi et al., 1997 [46] collectively describe the identification, molecular cloning and characterization of the inhibitor of NF-κB (IκB) kinases IKK-1 and IKK-2.
46. Zandi E, Rothwarf DM, Delhase M, Hyakawa M, Karin M. The IκB kinase complex(IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. of outstanding interest Cell. 91:1997;243-252 References by Zandi et al. and by Didonato et al., 1997 [41], Mercurio et al., 1997 [42], Regnier et al., 1997 [43] and Woronicz et al., 1997 [45] collectively describe the identification, molecular cloning and characterization of the inhibitor of NF-κB (IκB) kinases IKK-1 and IKK-2.
47. Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of IκBα by a novel ubiquitination-dependent protein kinase activity. Cell. 84:1996;853-862.
48. Schouten GL, Vertegaal ACO, Whiteside ST, Israel A, Toebes M, Dorsman JC, van der Eb AJ, Zantema A. IκBα is a target for the mitogen-activated 90 kDa ribosomal S6 kinase. of special interest EMBO J. 16:1997;3133-3144 Data presented here show that p90 ribosomal S6 kinase is also able to activate nuclear factor (NF)-κB by specifically phosphorylating the inhibitor of NF-κB (IκB)α in response to phorbol ester. This is strong biochemical evidence that the IκB kinases IKK-1 and IKK-2 are not the sole IκB kinases.
49. Weih F, Warr G, Yang H, Bravo R. Multifocal defects in immune responses in RelB-deficient mice. J Immunol. 158:1997;5211-5218.